Pliant Therapeutics Inc
PLRX1.140USD
+0.050+4.59%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
70.05MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Pliant Therapeutics Inc Unternehmen
Pliant Therapeutics, Inc. is a late-stage biotechnology company, which is focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1.
Pliant Therapeutics Inc Informationen
BörsenkürzelPLRX
Name des UnternehmensPliant Therapeutics Inc
IPO-datumJun 03, 2020
CEOCoulie (Bernard J)
Anzahl der mitarbeiter171
WertpapierartOrdinary Share
GeschäftsjahresendeJun 03
Addresse331 Oyster Point Boulevard
StadtSOUTH SAN FRANCISCO
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl94080
Telefon16504816770
Websitehttps://pliantrx.com/
BörsenkürzelPLRX
IPO-datumJun 03, 2020
CEOCoulie (Bernard J)
Führungskräfte von Pliant Therapeutics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Bernard J. Coulie, M.D., Ph.D.
Dr. Bernard J. Coulie, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
616.26K
-89375.00%
Dr. Hoyoung Huh, M.D., Ph.D.
Dr. Hoyoung Huh, M.D., Ph.D.
Non-Executive Chairman of the Board, Lead Independent Director
Non-Executive Chairman of the Board, Lead Independent Director
99.76K
--
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
35.08K
--
Dr. John T. Curnutte, M.D., Ph.D.
Dr. John T. Curnutte, M.D., Ph.D.
Independent Director
Independent Director
29.28K
--
Ms. Lily Cheung
Ms. Lily Cheung
Chief Human Resources Officer
Chief Human Resources Officer
7.22K
-15713.00%
Dr. Eric Lefebvre, M.D.
Dr. Eric Lefebvre, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Keith Cummings, M.D.
Dr. Keith Cummings, M.D.
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Gayle Crowell
Ms. Gayle Crowell
Independent Director
Independent Director
--
--
Mr. Christopher Keenan
Mr. Christopher Keenan
Vice President - Investor Relations and Corporate Communications
Vice President - Investor Relations and Corporate Communications
--
--
Mr. David E. I. Pyott, CBE
Mr. David E. I. Pyott, CBE
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Bernard J. Coulie, M.D., Ph.D.
Dr. Bernard J. Coulie, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
616.26K
-89375.00%
Dr. Hoyoung Huh, M.D., Ph.D.
Dr. Hoyoung Huh, M.D., Ph.D.
Non-Executive Chairman of the Board, Lead Independent Director
Non-Executive Chairman of the Board, Lead Independent Director
99.76K
--
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
35.08K
--
Dr. John T. Curnutte, M.D., Ph.D.
Dr. John T. Curnutte, M.D., Ph.D.
Independent Director
Independent Director
29.28K
--
Ms. Lily Cheung
Ms. Lily Cheung
Chief Human Resources Officer
Chief Human Resources Officer
7.22K
-15713.00%
Dr. Eric Lefebvre, M.D.
Dr. Eric Lefebvre, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Umsatzaufteilung
FY2024
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach RegionUSD
Name
Umsatz
Anteil
United States
0.00
0.00%
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Wed, Feb 4
Aktualisiert: Wed, Feb 4
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Tang Capital Management, LLC
9.77%
Woodline Partners LP
7.33%
Point72 Asset Management, L.P.
7.06%
Morgan Stanley & Co. LLC
5.69%
Citadel Advisors LLC
4.94%
Andere
65.21%
Aktionäre
Aktionäre
Anteil
Tang Capital Management, LLC
9.77%
Woodline Partners LP
7.33%
Point72 Asset Management, L.P.
7.06%
Morgan Stanley & Co. LLC
5.69%
Citadel Advisors LLC
4.94%
Andere
65.21%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
39.23%
Investment Advisor
22.12%
Investment Advisor/Hedge Fund
12.57%
Research Firm
12.08%
Individual Investor
2.40%
Family Office
0.87%
Venture Capital
0.76%
Private Equity
0.04%
Bank and Trust
0.02%
Andere
9.92%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
358
52.26M
85.04%
-35.89M
2025Q3
356
52.49M
85.42%
-37.39M
2025Q2
374
62.63M
102.02%
-15.09M
2025Q1
390
63.45M
103.37%
-12.99M
2024Q4
392
71.13M
116.20%
-8.66M
2024Q3
388
69.61M
114.50%
-7.63M
2024Q2
375
69.93M
115.87%
-7.66M
2024Q1
371
73.36M
121.74%
-3.24M
2023Q4
362
70.03M
116.83%
-95.89K
2023Q3
356
64.13M
107.25%
-2.06M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Tang Capital Management, LLC
6.00M
9.77%
+3.45K
+0.06%
Sep 30, 2025
Woodline Partners LP
4.50M
7.33%
+2.16M
+91.81%
Sep 30, 2025
Point72 Asset Management, L.P.
4.34M
7.06%
+4.34M
--
Sep 30, 2025
Morgan Stanley & Co. LLC
3.50M
5.69%
+1.50M
+75.33%
Sep 30, 2025
Citadel Advisors LLC
2.34M
3.81%
-16.43K
-0.70%
Sep 30, 2025
Blue Owl Capital Holdings LP
2.97M
4.83%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
2.78M
4.52%
-226.41K
-7.54%
Sep 30, 2025
Acadian Asset Management LLC
2.37M
3.86%
+739.13K
+45.33%
Sep 30, 2025
J.P. Morgan Securities LLC
2.13M
3.46%
+171.21K
+8.76%
Sep 30, 2025
Two Sigma Investments, LP
1.86M
3.02%
+1.11M
+148.96%
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
iShares Micro-Cap ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Biotechnology ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
DFA Dimensional US Core Equity Market ETF
0%
Schwab U.S. Small-Cap ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Humankind US Stock ETF
0%
iShares Morningstar Small-Cap Value ETF
0%
Mehr Anzeigen
iShares Micro-Cap ETF
Anteil0.02%
Invesco RAFI US 1500 Small-Mid ETF
Anteil0.01%
ProShares Ultra Nasdaq Biotechnology
Anteil0.01%
iShares Biotechnology ETF
Anteil0.01%
Invesco Nasdaq Biotechnology ETF
Anteil0.01%
DFA Dimensional US Core Equity Market ETF
Anteil0%
Schwab U.S. Small-Cap ETF
Anteil0%
Global X Russell 2000 Covered Call ETF
Anteil0%
Humankind US Stock ETF
Anteil0%
iShares Morningstar Small-Cap Value ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
